Nalmefene for treatment of alcohol dependence

被引:24
作者
Soyka, Michael [1 ,2 ]
Roesner, Susanne [1 ]
机构
[1] Univ Munich, Hosp Psychiat, D-80336 Munich, Germany
[2] Private Hosp Meiringen, CH-3860 Meiringen, Switzerland
关键词
alcohol; alcoholism; nalmefene; opioid antagonists; opioid receptors; therapy; MU-OPIOID-RECEPTOR; POSITRON-EMISSION-TOMOGRAPHY; NUCLEUS-ACCUMBENS; BETA-ENDORPHIN; FUNCTIONAL POLYMORPHISM; MICRODIALYSIS PROFILE; DOUBLE-BLIND; ANTAGONIST NALMEFENE; NALTREXONE TREATMENT; ENDOGENOUS OPIOIDS;
D O I
10.1517/13543784.2010.522990
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Alcohol use and dependence are frequent disorders. Despite numerous established psychosocial approaches, relapse to heavy drinking is common in alcohol-dependent patients after detoxification and relapse prevention remains a significant medical challenge. Areas covered in this review: The opioidergic system plays a crucial role in mediating the rewarding effects of alcohol, in part by modulating dopaminergic neurotransmission in mesolimbic brain areas. This review will discuss the neurochemical basis of alcoholism with respect to the opiodergic system. Nalmefene is an alternate opioid receptor that also targets the kappa opioid receptors and thus offers a different treatment approach. The treatment studies conducted so far are discussed. What the reader will gain: We present a comprehensive overview of the implication of the opioidergic system in mediating the rewarding effects of alcoholism and the preclinical and clinical studies conducted so far with nalmefene. Take home message: Although the number of clinical studies conducted with naltrexone by far exceeds the number conducted with nalmefene, the four studies on nalmefene published so far may indicate a role of this opioid antagonist in the treatment of alcoholism. Results of some ongoing studies on nalmefene will provide additional data on its use for this indication.
引用
收藏
页码:1451 / 1459
页数:9
相关论文
共 88 条
  • [81] Emerging drugs to treat alcoholism
    Soyka, Michael
    Roesner, Susanne
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2010, 15 (04) : 695 - 711
  • [82] Drugs for relapse prevention of alcoholism: ten years of progress
    Spanagel, Rainer
    Kiefer, Falk
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (03) : 109 - 115
  • [83] Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
    Spanagel, Rainer
    [J]. PHYSIOLOGICAL REVIEWS, 2009, 89 (02) : 649 - 705
  • [84] The effect of repeated administration of morphine, cocaine and ethanol on mu and delta opioid receptor density in the nucleus accumbens and striatum of the rat
    Turchan, J
    Przewlocka, B
    Toth, G
    Lason, W
    Borsodi, A
    Przewlocki, R
    [J]. NEUROSCIENCE, 1999, 91 (03) : 971 - 977
  • [85] A functional polymorphism of the μ-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers
    van den Wildenberg, Esther
    Wiers, Reinout W.
    Dessers, Joelle
    Janssen, Rob G. J. H.
    Lambrichs, Ellen H.
    Smeets, Hubert J. M.
    van Breukelen, Gerard J. P.
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2007, 31 (01) : 1 - 10
  • [86] Compulsive alcohol drinking in rodents
    Vengeliene, Valentina
    Celerier, Evelyne
    Chaskiel, Lea
    Penzo, Franco
    Spanagel, Rainer
    [J]. ADDICTION BIOLOGY, 2009, 14 (04) : 384 - 396
  • [87] Pharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence
    Walker, Brendan M.
    Koob, George F.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2008, 33 (03) : 643 - 652
  • [88] Association of the κ-opioid system with alcohol dependence
    Xuei, X.
    Dick, D.
    Flury-Wetherill, L.
    Tian, H-J
    Agrawal, A.
    Bierut, L.
    Goate, A.
    Bucholz, K.
    Schuckit, M.
    Nurnberger, J., Jr.
    Tischfield, J.
    Kuperman, S.
    Porjesz, B.
    Begleiter, H.
    Foroud, T.
    Edenberg, H. J.
    [J]. MOLECULAR PSYCHIATRY, 2006, 11 (11) : 1016 - 1024